By Jonathan Stempel NEW YORK (Reuters) -UnitedHealth Group was sued on Wednesday for allegedly concealing how backlash from the killing of a top executive was damaging its business, causing its stock to nosedive after the insurer lowered its 2025 outlook. In a proposed class action filed in Manhattan federal court, shareholders said the insurer defrauded them after the December 4 shooting of UnitedHealthcare Chief Executive Brian Thompson by shifting away from strategies that led to higher-than-average claims denials, without revealing the impact on profitability. UnitedHealth shares fell 22.4% on April 17, wiping out about $119 billion of market value, after the insurer cut its 2025 forecast for adjusted profit per share to between $26 and $26.50 from between $29.50 and $30. The insurer cited higher costs in its Medicare business. It had issued the old forecast one day before Thompson's death. Shareholders said UnitedHealth had previously inflated its stock price by recklessly sticking with its old forecast, even as mounting public anger and an October 17 U.S. Senate report on claims denials caused it to become more patient-friendly. UnitedHealth had no immediate comment. The insurer has offices in Eden Prairie, Minnesota and Washington, D.C. Wednesday's lawsuit seeks unspecified damages for UnitedHealth shareholders from between December 3, 2024 and April 16, 2025. Chief Executive Andrew Witty and Chief Financial Officer John Rex are also defendants. Luigi Mangione has pleaded not guilty to murdering Thompson in midtown Manhattan, and could face the death penalty. Mangione has become a hero to some Americans who are unhappy with for-profit health insurers that deny coverage for treatments. The case is Faller v UnitedHealth Group Inc et al, U.S. District Court, Southern District of New York, No. 25-03799. (Reporting by Jonathan Stempel in New York; Editing by Chizu Nomiyama) View Comments
UnitedHealth sued by shareholders over its reaction to backlash from executive's killing
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...